Currently, PAD inhibitors are widely studied as potential anti-cancer and anti-inflammatory drugs, and they can dramatically attenuate the disease course, severity, and clinical manifestations in many disease models, including collagen-induced arthritis [8], MS [9], colitis [10,11], atherosclerosis [12], lupus [13], kidney injury [14], hypoxic ischemia [15], and cancer [11,16]. This evidence concerns the gene PADI4 and systemic lupus erythematosus.